The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls ...

Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.

Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...

President Donald Trump’s pick to lead the US Food and Drug Administration told senators in a tense confirmation hearing ...

FDA drug alerts in endocrinology, including drug approvals, drug warnings, FDA medical device recalls, and FDA drug label ...

At a hearing, Dr. Marty Makary, the nominee for F.D.A. commissioner, fielded questions focused on whether he would review or ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes ...

Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...

today announced that its next-generation automated insulin delivery (AID) algorithm, Control-IQ+ technology (Control-IQ+), ...

Dr. Marty Makary will testify before the Senate health committee on Thursday. Lawmakers may press him over staff reductions ...

Biocon Biologics' own Insulin Aspart drug product for the US is currently under review by the US Food and Drug Administration ...

Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.